Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEASE trial of anti-TNF cessation in low-risk Crohn's disease
NL-OMON25895Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab and adalimumab in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Luminal clinical relapse component, Luminal biochemical relapse component and 2 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
infliximabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON25895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25895.